

Title (en)
CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED THIAZOLES AND RELATED DERIVATIVES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR[GAMMA]

Title (de)
CARBOXAMID- ODER SULFONAMIDSUBSTITUIERTE THIAZOLE UND ZUGEHÖRIGE DERIVATE ALS MODULATOREN FÜR ORPHAN-NUKLEARREZEPTOR ROR?

Title (fr)
THIAZOLES SUBSTITUÉS PAR CARBOXAMIDE OU SULFONAMIDE ET DÉRIVÉS APPARENTÉS EN TANT QUE MODULATEURS DU RÉCEPTEUR NUCLÉAIRE ORPHELIN ROR[GAMMA]

Publication
EP 2855440 A1 20150408 (EN)

Application
EP 13727805 A 20130529

Priority
• EP 12004186 A 20120531
• US 201261653556 P 20120531
• EP 2013001593 W 20130529
• EP 13727805 A 20130529

Abstract (en)
[origin: WO2013178362A1] The invention provides modulators for the orphan nuclear receptor ROR γ and methods for treating ROR γ mediated diseases by administering these novel ROR γ modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide or sulfonamide containing cyclic compounds of Formula (1), (1'), (100), (100'), (200) and (200') and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof.

IPC 8 full level
A61K 31/427 (2006.01); **A61P 3/10** (2006.01); **A61P 17/06** (2006.01); **A61P 19/02** (2006.01); **C07D 239/28** (2006.01); **C07D 263/34** (2006.01); **C07D 277/56** (2006.01); **C07D 333/38** (2006.01); **C07D 413/12** (2006.01); **C07D 417/04** (2006.01); **C07D 417/12** (2006.01); **C07D 417/14** (2006.01); **C07D 493/08** (2006.01); **C07D 493/10** (2006.01); **C07D 495/10** (2006.01)

CPC (source: CN EP KR US)
A61K 31/4245 (2013.01 - CN); **A61K 31/426** (2013.01 - CN); **A61K 31/427** (2013.01 - CN KR); **A61K 31/428** (2013.01 - CN); **A61K 31/439** (2013.01 - CN); **A61K 31/4523** (2013.01 - CN); **A61K 31/454** (2013.01 - CN); **A61K 31/4709** (2013.01 - CN); **A61K 31/4725** (2013.01 - CN); **A61K 31/496** (2013.01 - CN); **A61K 31/506** (2013.01 - CN); **A61K 31/5377** (2013.01 - CN); **A61K 31/5386** (2013.01 - CN); **A61K 31/541** (2013.01 - CN); **A61P 1/00** (2017.12 - EP); **A61P 1/04** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 5/14** (2017.12 - EP); **A61P 7/04** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/00** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 13/12** (2017.12 - EP); **A61P 17/00** (2017.12 - EP); **A61P 17/04** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/00** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 21/04** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 33/02** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/02** (2017.12 - EP); **A61P 37/06** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 239/28** (2013.01 - CN EP US); **C07D 263/34** (2013.01 - CN EP US); **C07D 277/36** (2013.01 - CN EP US); **C07D 277/46** (2013.01 - CN EP KR US); **C07D 277/52** (2013.01 - CN EP US); **C07D 277/56** (2013.01 - CN EP KR US); **C07D 307/68** (2013.01 - CN EP US); **C07D 333/38** (2013.01 - CN EP US); **C07D 405/12** (2013.01 - CN EP US); **C07D 413/12** (2013.01 - CN EP US); **C07D 417/04** (2013.01 - CN EP KR US); **C07D 417/06** (2013.01 - CN EP US); **C07D 417/12** (2013.01 - CN EP KR US); **C07D 417/14** (2013.01 - CN EP US); **C07D 453/02** (2013.01 - CN EP US); **C07D 455/02** (2013.01 - CN EP US); **C07D 487/08** (2013.01 - CN EP US); **C07D 491/10** (2013.01 - CN EP US); **C07D 493/08** (2013.01 - EP US); **C07D 493/10** (2013.01 - EP US); **C07D 495/10** (2013.01 - CN EP US); **C07D 498/08** (2013.01 - CN EP US)

Citation (search report)
See references of WO 2013178362A1

Citation (examination)
• US 5668161 A 19970916 - TALLEY JOHN J [US], et al
• EP 2822946 A1 20150114 - LUPIN LTD [IN]
• WO 2005028456 A1 20050331 - SOLVAY PHARM BV [NL], et al
• US 2010280023 A1 20101104 - SUGAWARA MASAMORI [JP], et al
• US 2005065189 A1 20050324 - LANGE JOSEPHUS H M [NL], et al

Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)
BA ME

DOCDB simple family (publication)
WO 2013178362 A1 20131205; AR 091194 A1 20150121; AU 2013270036 A1 20141127; AU 2013270036 B2 20161201; BR 112014029868 A2 20170627; CA 2873877 A1 20131205; CA 2873877 C 20180807; CL 2014003277 A1 20150710; CN 104603118 A 20150506; CN 104603118 B 20171003; CN 107007597 A 20170804; CO 7160113 A2 20150115; CR 20150003 A 20150423; EA 028330 B1 20171130; EA 201491943 A1 20150730; EA 201791271 A1 20180131; EP 2855440 A1 20150408; GT 201400275 A 20170824; HK 1209117 A1 20160324; IL 235626 A0 20150201; IL 235626 B 20181129; JP 2015521193 A 20150727; JP 6225178 B2 20171101; KR 101742954 B1 20170602; KR 20150015031 A 20150209; MX 2014014614 A 20150212; NO 20141395 A1 20141230; NZ 702539 A 20161125; PE 20150229 A1 20150302; PH 12014502570 A1 20150121; SG 11201407919W A 20141230; TW 201400465 A 20140101; TW I511960 B 20151211; UA 117913 C2 20181025; US 10301272 B2 20190528; US 2015175562 A1 20150625; UY 34832 A 20131231

DOCDB simple family (application)
EP 2013001593 W 20130529; AR P130101872 A 20130529; AU 2013270036 A 20130529; BR 112014029868 A 20130529; CA 2873877 A 20130529; CL 2014003277 A 20141128; CN 201380028983 A 20130529; CN 201610921829 A 20130529; CO 14285938 A 20141230; CR 20150003 A 20150105; EA 201491943 A 20130529; EA 201791271 A 20130529; EP 13727805 A 20130529; GT 201400275 A 20141128; HK 15109827 A 20151008; IL 23562614 A 20141111; JP 2015514380 A 20130529; KR 20147037172 A 20130529; MX 2014014614 A 20130529; NO 20141395 A 20141120; NZ 70253913 A 20130529; PE 2014002224 A 20130529;

PH 12014502570 A 20141119; SG 11201407919W A 20130529; TW 102119215 A 20130530; UA A201413918 A 20130529;
US 201314403903 A 20130529; UY 34832 A 20130529